Expert Review of Clinical Pharmacology最新文献

Present and future of ulta-low- and low-dose triple combination therapy in hypertension: a clinical practice perspective. 超低和低剂量三联治疗高血压的现状和未来：临床实践的观点。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-10-17 DOI: 10.1080/17512433.2026.2750908

Moo-Yong Rhee, Jae-Sik Jang, Ki-Chul Sung, Anthony Rodgers

{"title":"Present and future of ulta-low- and low-dose triple combination therapy in hypertension: a clinical practice perspective.","authors":"Moo-Yong Rhee, Jae-Sik Jang, Ki-Chul Sung, Anthony Rodgers","doi":"10.1080/17512433.2026.2750908","DOIUrl":"10.1080/17512433.2026.2750908","url":null,"abstract":"Introduction: It is increasingly recognized that initial monotherapy is insufficiently effective for sustained blood pressure (BP) control in the large majority of people with hypertension. Ultra-low- and low-dose combination therapy has emerged as a strategy to overcome limitations of conventional monotherapy-based stepped care, including delayed or inadequate BP reduction, adverse-effect-related treatment discontinuation, poor adherence, and therapeutic inertia.Areas covered: This review summarizes the pharmacologic rationale and clinical evidence for ultra-low- and low-dose multidrug combination therapy. To identify clinical evidence, we searched PubMed/MEDLINE, Embase, Scopus, and the Cochrane Central Register of Controlled Trials from inception to 31 March 2026, supplemented by manual reference screening. This review addresses practical questions in routine practice, including its relationship with compelling indications, cardiovascular protection, appropriate patient selection, and whether it reduces adverse effects. Future implementation as simplified, protocolized treatment and add-on approaches in high-risk populations is also discussed.Expert opinion: Ultra-low- and low-dose triple single-pill combination therapy should be viewed not simply as the earlier use of more antihypertensive drugs, but as a scalable treatment-delivery platform. It may support safe and earlier sustained BP control by simplifying drug selection, enabling stepwise dose escalation, reducing pill burden, improving adherence and persistence, and overcoming therapeutic inertia.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-12"},"PeriodicalIF":3.6,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149192361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of minocycline-containing bismuth quadruple therapy for Helicobacter pylori infection: a single-center retrospective study. 含米诺环素铋四联疗法治疗幽门螺杆菌感染的疗效：一项单中心回顾性研究。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-10-13 DOI: 10.1080/17512433.2026.2749579

Xiaomin Wang, Liyan Dong, Guo Lin, Zhixin Jiang, Yue Hou, Wenxiu Zhang, Ying Ma, Yongguo Zhang, Jiang Chen, Xingshun Qi

{"title":"Efficacy of minocycline-containing bismuth quadruple therapy for Helicobacter pylori infection: a single-center retrospective study.","authors":"Xiaomin Wang, Liyan Dong, Guo Lin, Zhixin Jiang, Yue Hou, Wenxiu Zhang, Ying Ma, Yongguo Zhang, Jiang Chen, Xingshun Qi","doi":"10.1080/17512433.2026.2749579","DOIUrl":"https://doi.org/10.1080/17512433.2026.2749579","url":null,"abstract":"Background: Increasing antibiotic resistance has undermined Helicobacter pylori eradication. Despite a low resistance to minocycline, clinical evidence for minocycline-containing bismuth quadruple therapy (MCQT) limited. This retrospective study aimed to evaluate the clinical efficacy of MCQT.Research design and methods: Patients who had Helicobacter pylori infection by 13C-urea breath testing at our department from October 2024 to July 2025 were screened. They were classified into MCQT (minocycline-amoxicillin-acid-inhibitors-bismuth [MAAB], minocycline-clarithromycin-acid-inhibitors-bismuth [MCAB], and minocycline-levofloxacin-acid-inhibitors-bismuth [MLAB]) and non-MCQT (amoxicillin-clarithromycin-acid-inhibitors-bismuth [ACAB] and amoxicillin-levofloxacin-acid-inhibitors-bismuth [ALAB]). Four comparisons (MAAB vs. ACAB, MCAB vs. ACAB, MLAB vs. ALAB, and MAAB vs. ALAB) were separately performed in treatment‑naïve and treatment‑experienced patients. Logistic regression analyses were used to identify the influence factors.Results: Overall, 687 treatment-naïve and 92 treatment-experienced Helicobacter pylori patients were included. MAAB demonstrated significantly higher eradication rates than ACAB in both groups (P = 0.020, P = 0.016), with no significant differences in other comparisons. Multivariate logistic regression analysis indicated that female was independently associated with a higher eradication rate in treatment-naïve patients in three comparisons (MAAB vs. ACAB, P = 0.021; MCAB vs. ACAB, P = 0.009; MAAB vs. ALAB, P = 0.043).Conclusions: MCQT achieve favorable Helicobacter pylori eradication rates in both treatment-naïve and treatment-experienced patients, and MAAB demonstrates a significantly higher eradication rate than ACAB.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149165153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pentosan polysulfate sodium and retinal safety: reconciling conflicting evidence and defining a pragmatic clinical pharmacology framework. 聚戊聚糖钠和视网膜安全：调和矛盾的证据和定义实用的临床药理学框架。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-10-12 DOI: 10.1080/17512433.2026.2747637

Shwetambari Ingawale, Hira Bakhtiar Khan, Mehwash Nadeem

{"title":"Pentosan polysulfate sodium and retinal safety: reconciling conflicting evidence and defining a pragmatic clinical pharmacology framework.","authors":"Shwetambari Ingawale, Hira Bakhtiar Khan, Mehwash Nadeem","doi":"10.1080/17512433.2026.2747637","DOIUrl":"https://doi.org/10.1080/17512433.2026.2747637","url":null,"abstract":"Introduction: Pentosan polysulfate sodium (PPS) remains an oral treatment option for selected patients with bladder pain syndrome, but recognition of PPS-associated pigmentary maculopathy has created uncertainty about long-term prescribing. The central clinical problem is that reported retinal-risk estimates vary markedly between studies.Areas covered: A narrative review of PubMed/MEDLINE, Embase, Scopus and Google Scholar was updated through 31 July 2026, with emphasis on clinical pharmacology, efficacy trials, case reports, ophthalmic screening cohorts, claims and population studies, pharmacovigilance, cumulative exposure, causality, regulatory guidance and screening recommendations. Study findings were compared according to population selection, exposure measurement, retinal ascertainment, follow-up and comparator design.Expert opinion: PPS-associated maculopathy is a credible exposure-related safety signal, although its absolute risk and individual susceptibility remain uncertain. Divergent estimates largely reflect differences in population selection, cumulative exposure range and retinal ascertainment rather than contradictory evidence. Cumulative exposure should inform review but not act as a mandatory stopping rule. We propose shared PPS stewardship, combining patient education and longitudinal shared decision-making with prescriber ownership of cumulative-exposure tracking and ophthalmic surveillance. Formal monitoring pathways are needed to support safe, equitable access to PPS while preserving individualized continuation or cessation decisions.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-13"},"PeriodicalIF":3.6,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149166049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Emerging pharmacological therapies for bronchiectasis. 新兴药物治疗支气管扩张。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-10-09 DOI: 10.1080/17512433.2026.2744253

Meghan Marmor, Mark Metersky

{"title":"Emerging pharmacological therapies for bronchiectasis.","authors":"Meghan Marmor, Mark Metersky","doi":"10.1080/17512433.2026.2744253","DOIUrl":"https://doi.org/10.1080/17512433.2026.2744253","url":null,"abstract":"Introduction: Bronchiectasis is a clinical syndrome characterized by dilated and thickened airways paired with clinical symptoms, most commonly a chronic suppurative cough that characteristically exacerbates. The disease can have burdensome symptoms that reduce quality of life. Pharmacologic treatments to date have been few and limited largely to antibiotic therapies. In recent years, bronchiectasis has been reconceived as a primary inflammatory disease, and drug development has since shifted to identify anti-inflammatory and immunomodulatory drugs.Methods: We conducted a targeted literature and clinical trial search to identify established and investigational pharmacotherapies for bronchiectasis. Seaches of PubMed, Google Scholar, UpToDate, OpenEvidence, and ClinicalTrials.gov were performed to identify published evidence, ongoing and completed clinical trials, and emerging therapeutic approaches.Areas covered: Herein, we review existing available therapies for patients with bronchiectasis. We then go on to review novel anti-inflammatory and immunomodulatory drugs as well as non-antibiotic anti-bacterial therapies in the development pipeline. We review drug safety, tolerability, efficacy, adverse reactions and cost considerations of therapy.Expert opinion: There are many potential treatments under investigation for bronchiectasis newly targeting airway inflammation. The effect size of the newer anti-inflammatory agents will likely be tied to a patient's unique inflammatory endotype. Future research should aim to identify clinically meaningful biomarkers that may allow clinicians to select the therapeutic agent best tailored to their disease.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-15"},"PeriodicalIF":3.6,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149147561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Limitations of current neuroprotective therapies in dementia with Lewy bodies. 当前神经保护疗法在路易体痴呆中的局限性。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-10-08 DOI: 10.1080/17512433.2026.2742316

Deirdre M O'shea, Shanell Disla, Alyssa E Gosling, German A Valdelamar, Magdalena Ioana Tolea, James E Galvin

{"title":"Limitations of current neuroprotective therapies in dementia with Lewy bodies.","authors":"Deirdre M O'shea, Shanell Disla, Alyssa E Gosling, German A Valdelamar, Magdalena Ioana Tolea, James E Galvin","doi":"10.1080/17512433.2026.2742316","DOIUrl":"https://doi.org/10.1080/17512433.2026.2742316","url":null,"abstract":"Introduction: Dementia with Lewy bodies (DLB) is characterized by progressive cognitive, neuropsychiatric, motor, autonomic, and sleep impairment. Pharmacological interventions developed with disease-modifying intent have entered clinical testing, but their biological rationale and adequacy of evaluation remain uncertain.Areas covered: This structured narrative review appraises pharmacological interventions developed with disease-modifying intent in DLB, focusing on biological rationale, central nervous system (CNS) exposure and target engagement, and whether trials adequately tested neuroprotection or altered clinical progression. PubMed/MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials were searched for studies published from January 2023 through 29 July 2026, with trial and registry reconciliation continuing through 30 July 2026. Twelve DLB trials evaluated interventions targeting endosomal signaling, kinase-related proteostasis, autophagy-lysosomal function, cellular bioenergetics, oligomer-associated synaptic injury, or neurotrophic signaling. No completed trial established neuroprotection or disease modification. Interpretation was limited by biological heterogeneity, Alzheimer disease co-pathology, incomplete CNS target-engagement evidence, short treatment duration, small samples, and endpoints unable to distinguish symptomatic effects from altered progression.Expert opinion: Future trials should prioritize biomarker-supported diagnosis, prospective co-pathology assessment, demonstrated CNS exposure and target engagement, and longer follow-up combining clinical and mechanism-linked outcomes.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149135652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Disitamab vedotin in urothelial carcinoma patients: a clinical trial perspective from ARON working group. 迪西他单维多汀在尿路上皮癌患者中的应用：来自ARON工作组的临床试验观点。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-10-07 DOI: 10.1080/17512433.2026.2744573

Concetta Calabrò, Francesco Ciccimarra, Anna Milella, Gerardo Cazzato, Mario Della Mura, Loredana Palermo, Jure Murgić, Tibor Szarvas, Kannan Sridharan, Maria Tereza Nieto-Coronel, Aly-Khan A Lalani, Olivier Mukuku, Anas Zayed, Cinthia Gauna, Chiara Paciolla, Raffaella Massafra, Oronzo Brunetti, Veronica Mollica, Francesco Massari, Matteo Santoni, Alessandro Rizzo

{"title":"Disitamab vedotin in urothelial carcinoma patients: a clinical trial perspective from ARON working group.","authors":"Concetta Calabrò, Francesco Ciccimarra, Anna Milella, Gerardo Cazzato, Mario Della Mura, Loredana Palermo, Jure Murgić, Tibor Szarvas, Kannan Sridharan, Maria Tereza Nieto-Coronel, Aly-Khan A Lalani, Olivier Mukuku, Anas Zayed, Cinthia Gauna, Chiara Paciolla, Raffaella Massafra, Oronzo Brunetti, Veronica Mollica, Francesco Massari, Matteo Santoni, Alessandro Rizzo","doi":"10.1080/17512433.2026.2744573","DOIUrl":"https://doi.org/10.1080/17512433.2026.2744573","url":null,"abstract":"Introduction: In recent years, studies have demonstrated that in urothelial carcinoma (UC), the rate of HER-2 protein overexpression (immunohistochemistry 2+ and 3+) ranges from 18.1% to 36%, and the rate of HER-2 gene amplification reaches 10%-23%. The advent of HER-2-targeted antibody-drug conjugates and immune checkpoint inhibitors has reshaped the treatment landscape of advanced urothelial carcinoma.Areas covered: In the current paper, we discuss the role of disitamab vedotin as an innovative anticancer therapy in UC patients, with a specific focus on available evidence and ongoing clinical trials. A literature search of PubMed/MEDLINE, Embase, Scopus, and ClinicalTrials.gov (through May 2026) was performed using the terms 'disitamab vedotin,' 'RC48-ADC,' and 'urothelial carcinoma.'Expert opinion: As ADC-based strategies continue to expand in UC, further studies will be needed to better understand how DV should be integrated with other anticancer approaches in this setting, particularly in terms of patient selection and treatment sequencing.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-11"},"PeriodicalIF":3.6,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149106051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AI-enabled digital therapeutics in pharmacy practice: prescription software, medication optimization, safety surveillance, and future clinical positioning. 药房实践中的人工智能数字疗法：处方软件、药物优化、安全监测和未来临床定位。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-10-01 Epub Date: 2026-09-26 DOI: 10.1080/17512433.2026.2739562

Wajid Zaman, Asma Ayaz

{"title":"AI-enabled digital therapeutics in pharmacy practice: prescription software, medication optimization, safety surveillance, and future clinical positioning.","authors":"Wajid Zaman, Asma Ayaz","doi":"10.1080/17512433.2026.2739562","DOIUrl":"10.1080/17512433.2026.2739562","url":null,"abstract":"Introduction: Digital therapeutics (DTx) are evidence-based software interventions that can function as therapeutic modalities, either independently or adjunctively, while artificial intelligence (AI) may support personalization, prediction, adaptive delivery, and safety monitoring. Pharmacy practice is directly affected because pharmacists manage medicines, adherence, counseling, pharmacovigilance, access, and longitudinal medication-related care.Areas covered: This structured narrative review defines digital health, digital medicine, DTx, prescription DTx (PDT), software as a medical device (SaMD), and AI-enabled DTx; critically examines clinical evidence and its limitations; and evaluates pharmacist roles in product selection, onboarding, monitoring, medication optimization, safety surveillance, reimbursement, and governance. PubMed and targeted regulatory and professional sources were searched through July 2026, with priority given to randomized trials, systematic reviews, meta-analyses, real-world evidence frameworks, and official guidance.Expert opinion: AI-enabled DTx should be regarded as therapeutic modalities whose role may be standalone or adjunctive according to intended use and evidence. They are distinct from pharmacological medicines, and they should not autonomously displace indicated drug therapy or professional judgment without comparative evidence. Pharmacist-supervised integration is proposed as a clinically accountable conceptual implementation model, but its effectiveness, cost-effectiveness, and workflow consequences require prospective validation.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"879-889"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149029877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Preventing psoriatic arthritis: is disease interception the next frontier in clinical pharmacology? 预防银屑病关节炎：疾病阻断是临床药理学的下一个前沿吗？

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-10-01 Epub Date: 2026-09-21 DOI: 10.1080/17512433.2026.2737173

Nikolaos Kougkas, George Fragoulis

引用次数: 0

Drug safety and pregnancy: more evidence or changing mindset? 药物安全与妊娠：更多证据或观念改变？

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-10-01 Epub Date: 2026-09-30 DOI: 10.1080/17512433.2026.2738821

Alain Braillon

引用次数: 0

Brensocatib in non-cystic fibrosis bronchiectasis: neutrophil serine protease modulation, clinical evidence, and therapeutic positioning. Brensocatib治疗非囊性纤维化支气管扩张：中性粒细胞丝氨酸蛋白酶调节、临床证据和治疗定位。

IF 3.6 3区医学

Expert Review of Clinical Pharmacology Pub Date : 2026-10-01 DOI: 10.1080/17512433.2026.2739561

Muhammad Saeed Akhtar

{"title":"Brensocatib in non-cystic fibrosis bronchiectasis: neutrophil serine protease modulation, clinical evidence, and therapeutic positioning.","authors":"Muhammad Saeed Akhtar","doi":"10.1080/17512433.2026.2739561","DOIUrl":"10.1080/17512433.2026.2739561","url":null,"abstract":"Introduction: Non-cystic fibrosis bronchiectasis (NCFB) is a chronic airway disease characterized by recurrent infection, mucus retention, neutrophilic inflammation, and pulmonary exacerbations. Brensocatib is an oral, selective, reversible dipeptidyl peptidase 1 (DPP1) inhibitor that reduces neutrophil serine protease activation and has received regulatory approval for non-cystic fibrosis bronchiectasis in patients aged 12 years and older.Areas covered: This review evaluates the mechanism, clinical pharmacology, efficacy, safety, regulatory status, and therapeutic positioning of brensocatib. Literature published through 30 June 2026 was identified through PubMed, Scopus, and SciFinder-n, supplemented by prescribing information, regulatory documents, bronchiectasis guidelines, and evidence from the phase 2 WILLOW and phase 3 ASPEN trials.Expert opinion: Brensocatib is a mechanism-directed preventive therapy for NCFB; the evidence base is strongest in patients with recent pulmonary exacerbations, while exact sequencing relative to macrolides and inhaled antibiotics remains uncertain. It should be integrated with airway-clearance and infection-directed management rather than viewed as a stand-alone intervention. Its long-term value will depend on appropriate patient selection, dermatologic and periodontal monitoring, affordability, comparative effectiveness, and real-world evidence on exacerbations, antibiotic use, lung-function trajectories, and patient-centered outcomes.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"891-901"},"PeriodicalIF":3.6,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149037458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0